WallStreetZenWallStreetZen

NASDAQ: ATOS
Atossa Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ATOS

Based on 2 analysts offering 12 month price targets for Atossa Therapeutics Inc

Min Forecast
$7.00+998.9%
Avg Forecast
$7.13+1,018.52%
Max Forecast
$7.25+1,038.15%

Should I buy or sell ATOS stock?

Based on 2 analysts offering ratings for Atossa Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ATOS's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ATOS as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ATOS stock forecasts and price targets.

ATOS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-21
lockedlocked$00.00+00.00%2025-03-26

1 of 1

Forecast return on equity

Is ATOS forecast to generate an efficient return?

Company
-39.76%
Industry
153.19%
Market
81.87%
ATOS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ATOS forecast to generate an efficient return on assets?

Company
-37.17%
Industry
36.07%
ATOS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ATOS earnings per share forecast

What is ATOS's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.25
Avg 2 year Forecast
-$0.30
Avg 3 year Forecast
-$0.27

ATOS revenue forecast

What is ATOS's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$13.9M
Avg 2 year Forecast
$67.7M
Avg 3 year Forecast
$144.5M

ATOS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ATOS$0.64$7.13+1,018.52%Buy
GALT$1.31$11.00+739.69%Buy
CLYM$1.23N/AN/A
HLVX$1.66$2.00+20.48%Hold
ENTX$1.84$10.00+443.48%Buy
View Top Biotech Stocks

Atossa Therapeutics Stock Forecast FAQ

Is Atossa Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ATOS) stock is to Buy ATOS stock.

Out of 2 analysts, 0 (0%) are recommending ATOS as a Strong Buy, 2 (100%) are recommending ATOS as a Buy, 0 (0%) are recommending ATOS as a Hold, 0 (0%) are recommending ATOS as a Sell, and 0 (0%) are recommending ATOS as a Strong Sell.

If you're new to stock investing, here's how to buy Atossa Therapeutics stock.

What is ATOS's earnings growth forecast for 2025-2027?

(NASDAQ: ATOS) Atossa Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Atossa Therapeutics's earnings in 2025 is -$25,504,000.On average, 2 Wall Street analysts forecast ATOS's earnings for 2025 to be -$32,292,501, with the lowest ATOS earnings forecast at -$32,292,501, and the highest ATOS earnings forecast at -$32,292,501. On average, 1 Wall Street analyst forecast ATOS's earnings for 2026 to be -$38,751,001, with the lowest ATOS earnings forecast at -$38,751,001, and the highest ATOS earnings forecast at -$38,751,001.

In 2027, ATOS is forecast to generate -$34,875,901 in earnings, with the lowest earnings forecast at -$34,875,901 and the highest earnings forecast at -$34,875,901.

What is ATOS's revenue growth forecast for 2028-2030?

(NASDAQ: ATOS) Atossa Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Atossa Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ATOS's revenue for 2028 to be $1,795,463,056, with the lowest ATOS revenue forecast at $1,795,463,056, and the highest ATOS revenue forecast at $1,795,463,056. On average, 1 Wall Street analysts forecast ATOS's revenue for 2029 to be $8,744,809,271, with the lowest ATOS revenue forecast at $8,744,809,271, and the highest ATOS revenue forecast at $8,744,809,271.

In 2030, ATOS is forecast to generate $18,665,065,578 in revenue, with the lowest revenue forecast at $18,665,065,578 and the highest revenue forecast at $18,665,065,578.

What is ATOS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ATOS) forecast ROA is -37.17%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is ATOS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ATOS price target, the average ATOS price target is $7.13, with the highest ATOS stock price forecast at $7.25 and the lowest ATOS stock price forecast at $7.00.

On average, Wall Street analysts predict that Atossa Therapeutics's share price could reach $7.13 by Apr 21, 2026. The average Atossa Therapeutics stock price prediction forecasts a potential upside of 1,018.52% from the current ATOS share price of $0.64.

What is ATOS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ATOS) Atossa Therapeutics's current Earnings Per Share (EPS) is -$0.20. On average, analysts forecast that ATOS's EPS will be -$0.25 for 2025, with the lowest EPS forecast at -$0.25, and the highest EPS forecast at -$0.25. On average, analysts forecast that ATOS's EPS will be -$0.30 for 2026, with the lowest EPS forecast at -$0.30, and the highest EPS forecast at -$0.30. In 2027, ATOS's EPS is forecast to hit -$0.27 (min: -$0.27, max: -$0.27).

What is ATOS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ATOS) forecast ROE is -39.76%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.